Cargando…
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
Resistance to immune checkpoint inhibitors (ICI) and other anticancer therapies is often associated with the accumulation of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) in the tumor microenvironment (TME). Therefore, targeting MDSC recruitment or function is of s...
Autores principales: | DeNardo, David G, Galkin, Anna, Dupont, Jakob, Zhou, Lei, Bendell, Johanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404448/ https://www.ncbi.nlm.nih.gov/pubmed/34452928 http://dx.doi.org/10.1136/jitc-2021-003005 |
Ejemplares similares
-
Correction: GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
Publicado: (2021) -
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
por: Rehman, Hasan, et al.
Publicado: (2016) -
‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies?
por: Pettinger, Claire, et al.
Publicado: (2022) -
Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine
por: Page, David B., et al.
Publicado: (2016) -
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
por: Grigg, Claud, et al.
Publicado: (2016)